Stay updated with breaking news from Nello Mainolfi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting Additional KT-621
Operator: Good day, and welcome to the Kymera Therapeutics First Quarter 2024 Results Conference Call. All participants will be in the listen-only mode.
02.05.2024 - KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in the first half of ...
New preclinical data on novel E3 pairing and structural mechanisms for KT-333, a First-in-Class STAT3 degrader, presented in AACR’s late-breaking poster session Nello Mainolfi, Founder, President and CEO of Kymera, invited as a featured speaker in AACR’s Major Symposium to discuss drug discovery and clinical translation strategies for STAT3 and MDM2 degrader programs KT-333 and KT-253 Phase 1 dose escalation studies ongoing with additional data expected in 2024 WATERTOWN, Mass., April 08, 2024 (
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2023 Earnings Call Transcript February 22, 2024 Kymera Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.25, expectations were $-0.44. KYMR isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to the […]